MedTrace Logo

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O )

NCT04426201 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2024-04-11

No results posted yet for this study

Summary

Comparison of the effects of CYT107 vs Placebo administered IM at 10μg/kg twice a week for three weeks on immune reconstitution of lymphopenic COVID-19 patients

Conditions

Interventions

DRUG

CYT107

IM administration at 10µg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay

DRUG

Placebo

Same number, volume and frequency of IM administration of saline

Sponsors & Collaborators

  • Memorial Sloan Kettering Cancer Center

    collaborator OTHER

  • Amarex Clinical Research

    collaborator OTHER

  • M.D. Anderson Cancer Center

    collaborator OTHER

  • Cancer Research Institute, New York City

    collaborator OTHER

  • Revimmune

    lead INDUSTRY

Principal Investigators

  • Steve Pastores, MD · Memorial Sloan Kettering Cancer Center

  • Marcel van den Brink, MD, PhD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-20
Primary Completion
2022-06-30
Completion
2022-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04426201 on ClinicalTrials.gov